Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside

Glioblastoma multiforme (GBM) is an aggressive and dismal disease with a median overall survival of around 15 months and a 5-year survival rate of 7.2%. Owing to genetic mutations, drug resistance, disruption to the blood–brain barrier (BBB)/blood–brain tumor barrier (BBTB), and the complexity of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yutao, Sharma, Amit, Maciaczyk, Jarek, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835986/
https://www.ncbi.nlm.nih.gov/pubmed/35163235
http://dx.doi.org/10.3390/ijms23031311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835986/
https://www.ncbi.nlm.nih.gov/pubmed/35163235
http://dx.doi.org/10.3390/ijms23031311

Ejemplares similares